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Asingle intraperitoneal injection of bacterial cell walls derived from groupA strep-
tococci (SCW)' into susceptible rats results in the development of acute and chronic
erosive polyarthritis (1, 2) . The pathology of the lesion leading to joint destruction
has been shown to be aT cell-dependent, cell-mediated response to the deposition
of the group A streptococcal peptidoglycan-polysaccharide polymers in the syno-
vium (3-5) . Furthermore, these chronic joint lesions share many common histo-
pathologic, radiologic, and clinical features with human rheumatoid arthritis (6) .
Another apparent shared feature in patients with rheumatoid arthritis and rodents
with SCW-induced arthritis is impaired immunoregulation and suppression of the
immune system . Patients with arthritis frequently exhibit suppressed lymphoid cell
functions (6-10), and depressed lymphoid cell activity has also been reported inSCW
treated rats (2, 11, 12) . The mechanism of aberrant immune responsiveness associated
with these chronic inflammatory lesions is unknown, although adherent cells have
been implicated (2, 10) and deficient IL-2 production has also been reported (11) .
Because of thepotential importance of impaired immunoregulation in the evolu-
tion of chronic inflammatory lesions such as arthritis, we have used theexperimental
model ofSCW-induced chronic inflammation to explore the cellular and molecular
pathways of suppressed immune responsiveness . In this study, we document a role
forthe adherent macrophage population in mediating the suppressed lymphoprolifer-
ative responses characteristic of the spleens of SCW-treated Lewis (LEW) rats . Fur-
thermore, this suppression is mediated by a soluble suppressor factor released by
SCW-activated macrophages within the spleen . Subsequent studies to characterize
this suppressor activity revealed it to be consistent with thepolypeptide, transforming
growth factor R (TGRR) .
Materials and Methods
Animals.
￿
Specific pathogen-free inbred Lewis (LEW) female rats (100 g) (Charles River
Breeding Laboratories, Inc., Wilmington, MA) were injected with preparations of
peptidoglycan-polysaccharide fragments from SCW prepared as described (2, 3). A sterile
aqueous suspension ofsonicatedSCWin PBS, pH 7.4 (National Institutes of Health Media
' Abbreviations used in this paper: LEW, Lewis ; SCW, group A streptococcal cell walls; TGFS, trans-
forming growth factor P .
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Unit), was injected intraperitoneally at an optimal dose equivalent to 30 pg of cell wall rham-
nose per gram body weight. Control rats received PBS only, and all animals were monitored
for the development of clinically identifiable arthritis.
Spleen Cell Proliferation and Supernatant Production.
￿
Spleens were excised at various intervals
afterSCW injection and from control animals and single cell suspensions prepared (13). Data
is presented from spleens obtained 3 wk after SCW administration unless otherwise indi-
cated. Proliferation was determined by culturing 2 x 105 cells/200 Al DMEM containing
50 pg/ml gentamicin, 2 mM glutamine, 5 x 10-5 M 2-ME, and 1% normal rat serum in
microtiter wellswith PHA (Burroughs Wellcome Co., Greenville, NC) or Con A (Calbiochem-
Behring Corp., San Diego, CA) (13). After 68 h of culture, the cells were pulsed 4 h with
0.5 gCi/well of [3H]thymidine ([3H]TdR; sp act, 6.7 Ci/mmol, Becton Dickinson & Co.,
Mountain View, CA). The cultures were harvested with an automated harvester (PhD., Cam-
bridge Technology, Inc., Cambridge, MA) and processed for determination of [3H]TdR in-
corporation. All data are means of triplicates in which the SE were routinely <10% of the
mean. For coculture experiments, spleen cellswere separated into adherent and nonadherent
populations by adhering the spleen cells for 2-4 h followed by repeated washing. The recov-
ered nonadherent cellswere resuspended in DMEM, counted, and cultured in the presence
or absence of adherent cell populations (>90% macrophages by nonspecific esterase staining).
Cytokine-enriched supernatants were generated by incubating 2 x 106 unseparated spleen
cells, adherent cells, or nonadherent cellsin 1 ml serum-freeDMEM without stimuli or with
5 pg/ml Con A, 5 pg/ml PHA, or 10 pg/ml LPS (055:135; Difco Laboratories Inc., Detroit,
MI) for 24-48 h. In certain experiments, culture supernatants were preincubated with a pre-
viously determined optimal concentration of a rabbit IgG antibody that neutralizes both TGF
(31 and TGFp2 (R & D Systems, Inc., Minneapolis, MN). Dependent upon the assay, 10-50
jig of IgG neutralize the activity of 1 ng/ml of TGF-p, and therefore, we routinely added
5 pg IgG in 5 pl PBS to 100 pl of supernatant. Equivalant concentrations of normal rabbit
IgG (kind gift of Dr. R. Mage, National Institute ofAllergy and Infectious Diseases) were
added to parallel aliquots of supernatant as a control.
Identification of Cell Subpopulations, SCW, and TGF--/3 in Rat Spleens.
￿
Spleens were flash frozen
in O. C. T. Compound (Miles Scientific Div., Naperville, IL), sectioned, fixed in acetone,
and preincubated for 10 min with a 1 :200 dilution of horse serum and rat serum (3). The
following mAbs were used in combination with an immunoperoxidase staining technique
(ABC VectaStain Kit; Vector Laboratories, Inc., Burlingame, CA) for identification of spleen
mononuclear cell subpopulations: W3/13 (pan T lymphocytes), OX19 (pan T lymphocytes),
W3/25 (CD4 helper/inducer lymphocytes), OX8 (CD8, suppressor/cytotoxic lymphocytes),
OX-43 (macrophages), and la (Accurate Chemical & Scientific Corp., Westbury, NY). Addi-
tional spleen sections were stained with a rabbit antibody to the group A-specific SCW (3)
or with an antibody to TGFp prepared against a synthetic polypeptide identical to NH2-
terminal residues 1-30 of TGF0 (14). Control sections were stained as above without the
primary antibody or with an irrelevant mAb.
In additional studies, singlecell suspensions from spleens ofSCWtreated and control animals-
were incubated at 4°C (5 x 105 cells/50 pl staining buffer containing 0.1% NaN3 and 2%
FCS) with 10 gl of a 1 :500 dilution ofthe above antibodies, washed, and then incubated with
a FITC-goat (Fab')2 anti-mouse Ig antibody (Tago Inc., Burlingame, CA). The cells were
washed and suspended in 2 % paraformaldehyde before analysis by flow microfluorometry
(FACStar; Becton Dickinson & Co., Sunnyvale, CA) as described (15).
IL-2 Assay.
￿
Supernatants were assayed for IL-2 activity by their ability to support the
growth of the murine IL-2-dependent CTL-L line (13). The CTL-L cells were cultured in
the presence of threefold dilutions of the spleen cell supernatants in parallel with an IL-2
standard containing 100 U/ml for 48 h. The triplicate cultures were pulsed with 0.5 PCi
[3H]TdR (sp act, 1.9 Ci/mmol) for 4 h, and the incorporated radioactivity was determined.
The IL-2 activity in test samples is presented as units of IL-2 based on comparison with the
titration curve of the IL-2 standard.
IL-1 Assay.
￿
Supernatants (twofold dilutions) were assayed for IL-1 activity in cultures of
thymocytes from 6-wk-old C3H/HeJ mice with suboptimal concentrations ofPHA (13). During
the final 5 h of incubation, the cultures were pulsed with 0.5 pCi/well [3H]TdR, the incor-porated radioactivity was determined, and the data were transformed into units by compar-
ison to the IL-1 standard (Genzyme, Boston, MA) containing 100 U/ml.
Northern BlotAnalysis.
￿
Total RNA was isolated from spleens obtained from SCWinjected
or control animals 12 h to 3 wk after SCW administration. Total RNA was extracted with
guanidine thiocyanate as described (16). The RNA samples (10.0 Ag) were subjected to elec-
trophoresis in a formaldehyde-containing agarose gel and transferred to nitrocellulose paper.
The filters containing spleen cell RNA were prehybridized for at least 4 h and then hybrid-
ized overnight at 42 °C with a 12p-labeled Eco RI insert of TGFp obtained from Genentech
(S. San Francisco, CA). The filters were exposed to Kodak XAR5 film with intensifier screens
at -70°C for 4-18 h. Relative amounts of mRNA present on the filter were monitored by
stripping the blots and then hybridizing with a 32p-labeled plasmid encoding rat glyceralde-
hyde-3-phosphate-dehydrogenase (17).
Results
Deficient Lymphoproliferative Responses in SCW-injected LEWRats.
￿
Spleen cells ob-
tained from LEW rats 3 wk after a single intraperitoneal injection of SCW were
compared with age-matched control LEW rat spleen cellsfor their ability to proliferate
in response to T cell mitogens. As evident in Fig. 1, spleen cells from the SCW-
injected animals did not proliferate to either Con A or PHA in contrast to similar
spleen cell cultures from LEW control animals. This deficient lymphoproliferative
response was independent of antigen, mitogen, dose, cell concentration, duration
of culture, or differences in cell viability. Evaluation of lymphocyte function at var-
ious time points after SCW administration revealed that within 18 h the prolifera-
tive response was suppressed. This immune-deficient state continued through the
development of acute arthritic symptoms (days 3-5) and persisted during the evolu-
tion of the chronic erosive joint lesions (>3 wk) (Fig. 2). Suppressed lymphocyte
DNA synthesis in response to in vitro stimulation was also apparent in cells obtained
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FIGURti 1. Suppressed lymphocyte
mitogenesis after SCW injection.
Spleen cells prepared from LEW rats
3 wk aftera single intraperitoneal in-
jection ofSCW(LI) or control animals
(LC) were cultured with 0-10 ug/ml
Con Aor PHAfor 72 h. The triplicate
cultures were pulsed with [3H]TdR
and processed for determination of
mitogenic activity. Data are represen-
tative of 10 experiments.1406
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Kinetics of SCW-induced
immunosuppression. Spleen cells were
obtained from animals 18 h to 21 wk
afterasingle intraperitoneal injection
of SCW(LI) or from age-matched con-
trol animals (LC) andchallenged with
an optimal dose of Con A (5 erg/ml).
Data arerepresentative offour to eight
animals at each time interval.
from draining lymph nodes and in PBMC from the SCW-injected animals (data
not shown).
Cytokine Production by Spleen Cellsfrom Normal andSCW-treated LEWRats.
￿
To deter-
mine whether the spleen cell dysfunction was a consequence of a deficiency in the
generation ofcytokinesthat promote mitogenesis, IL-1 and IL-2 levels were quanti-
tated in the spleen cell culture supernatants (Fig. 3). Levels of IL-2 produced by
spleen cell cultures from SCW-treated animals in response to Con A challenge were
frequently -50% of those produced by control spleen cells under similar conditions
(Fig. 3 A) as recently reported (11). However, the production of IL-2 in response
to PHA stimulation was only marginally reduced in the SCW-injected rat spleen
cell cultures. These data suggested that although reduced IL-2 levels might con-
tribute to the decreased proliferative response, IL-2 deficiency likely could not be
considered the sole mechanism responsible for the immunosuppression. Further-
more, the addition of exogenous IL-2 (up to 100 U/ml) was ineffective in reversing
the depressed mitogenic response (data not shown).
Similarly, IL-1 production by cultures ofspleen cellsfrom SCW-treated rats stimu-
lated with LPS in vitro was not significantly diminished compared with controls
(Fig. 3 B), and in adherent spleen cell-enriched populations the IL-1 levels were
frequently foundto be elevated. IL-1 added to spleen cell cultures from SCW-treated
rats did not augmentthe mitogen-induced proliferation. In further studiesto evaluate
cytokine production, both granulocyte-macrophage colony stimulating factor and
IL-3 synthesis were not significantly different between mitogen-stimulated control
and SCW spleen cell cultures (data not shown). Thus, these data collectively dem-
onstrate that adeficiency in cytokine production is probably not the primary mech-
anismresponsible forthe suppressed proliferative responses, andthat additional mech-
anisms whereby SCW mediates immunosuppression must be operative.
Role ofAdherent Cells in MediatingImmunosuppression.
￿
Since a deficiency in mono-
nuclear cell-derived cytokines necessary for cell growth could not account for the
lack ofmitogenesis, spleen cells from LEWinjected and LEW control animals were
compared for aberrations in cellular subsets which might explain the nature of theG
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IL synthesis by control and SCW-injected spleen cells. Spleen cells were cultured
at 2 x 106/mlin thepresence or absence of PHA(5 gg/ml), ConA (5 Pg/ml), or LPS (10Jig/ml)
for 48 h. (A) Supernatants were harvested and assayed for IL-2 on the CTL-L cell line as de-
scribed in Materials andMethods. Data representmean U/ml IL-2 from six different animals.
(B) IL-1 from LPS-stimulated culture supernatants was quantitated in the thymocyte costimu-
lator assay.
suppression. Although an increase in the T cell suppressor population might be an-
ticipated, we and others (11) could not demonstrate an increase in the percentage
of cells that stained positively for the CD8 marker in immunocytochemical analysis
of spleen tissue sections or by FRCS analysis (20.5 f 7.2% CD8+ in control vs.
14.5 ± 6.01% in 6 SCW injected). CD4+ helper T cells transiently increased in
percentage, although notsignificantlyabovecontrols. Theonly consistent alteration
in subsets observed was an increase in OX43+ staining, which identifies certain
monocyte-macrophage populations (18). Control spleens contained 2-5% OX43+
cells, whereas 5-25% OX43+ cells were identified in the spleens of SCW-injected
animals depending on the interval after treatment. To determine if this increase in
monocyte-macrophages wascontributing to the suppressed Tcell response, thespleen
cells from control and SCW-treatedanimalswere separated into adherent and nonad-
herent cell populations before culture with mitogens. Depletion of adherent cells
from LEW control spleen cell populations resulted in diminished mitogen-induced
DNA synthesis, likely dueto loss of accessory cell function (Fig. 4A and B). In con-
trast, removal ofadherent cellsfrom theSCWinjected spleen cell preparations resulted
in dramatically enhanced T cell proliferation to Con A (Fig. 4 A) and PHA (Fig.
4 B) to normal or near normal levels. These data clearly indicated that the defect
in T cell proliferation was reversible and also, that it was mediated by adherent cells.
Furthermore, T lymphocytes themselves are likely not defective in IL-2 synthesis,
IL-2-R expression, or other parameters of growth since the T cells functioned nor-
mally after removal of adherent cells.
To further document the role of the adherent spleen cells (>90% macrophages)1408
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Restoration of lymphocyte mitogenesis by adherent cell depletion. Spleen cells (2
x 101)/ml from control (LC) and SCW-injected (LI) animalswere cultured for 2-4 h, andthe
nonadherent cells were harvested, counted, and cultured (2 x 105/200 wl) in the presence or
absenceof Con A (5 ug/ml) or PHA (5 Wg/ml) for 72 h. Mitogenic activity in thetriplicate cul-
tures wasdetermined aftera 4-h pulsewith [ H]TdR. Data are representative of four to six ex-
periments.
from the SCW-treated animals in inhibiting lymphocyte proliferation, adherent cells
from SCWinjected animals were cocultured with nonadherent spleen cells from control
animals (Fig. 5 A and B, LI adh and LC nonadh). Under these conditions, marked
suppression of the mitogen response of the control lymphocytes was observed. In
contrast, control adherent cell populations cocultured with control nonadherentcells
(Fig. 5, LC nonadh andLCadh) demonstrated vigorous proliferationto both mitogens.
Cultures containing adherent cellsfrom SCWtreated animals and nonadherent spleen
cells from the same animals (Fig. 5, LI adh and LI nonadh, respectively) exhibited
no proliferation in response to Con A or PHA (Fig. 5, A and B) . After in vivo ex-
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FIGURE 5.
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Effect of adherent
cell populations on spleen cell
mitogenic activity. Spleen cells
(2 x 105/200 ul) from control
(LC) or SCW injected (LI)
animals were cultured for 2-4
h in microtiter wells. Thenon-
adherent cells were recovered
and cocultured with adherent
cells from LC or LI cultures for
72 hin thepresence oftheindi-
cated concentrations of ConA
or PHA. Mitogenic activity in
thetriplicate cultures was deter-
mined after a 4-h pulse with
[3H]TdR. Data are representa-
tive of four to six experiments.
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Nposure to SCW, adherent spleen macrophages appear to exhibit profound inhibi-
tory effects on T lymphocyte mitogenic activity.
MechanismofAdherent Cell Suppression.
￿
Effortswere subsequently directed at defining
themechanisms wherebythe adherent macrophages suppressed lymphocyte prolifer-
ation. Thepossibility ofasoluble suppressor factor wasexplored by culturing spleen
cell populations from control and SCWinjected rats without any exogenousstimuli
for 24-48 h, collecting the cell-free supernatants, and then adding these superna-
tants to cultures of control spleen cells in the presence of Con A. The addition of
supernatants obtained from LC spleen cultures augmented the mitogenic response
of Con A-stimulated control spleen cells(Fig. 6) . In contrast, supernatants obtained
from parallel SCW-injected rat spleen cell cultures suppressed thenormal mitogenic
response from 10 to 80%, dependent upon concentration and kinetics (Fig. 6, LI
1-3) . These data supported the notion that a macrophage-dependent soluble sup-
pressor molecule(s) was generated after exposure to the bacterial cell walls in vivo.
Initial attempts to define this suppressor molecule involved the addition of inhibi-
tors of several previously defined macrophage suppressor molecules including
prostaglandins (19) and reactive oxygen intermediates (20). Although SCW added
directly to spleen cell and/or macrophage cultures induces PGE2 synthesis and 02
generation (Feldman et al ., manuscript in preparation), the addition of indometh-
acin (10-6 M), superoxide dismutase (up to 600 leg/ml) and/or catalase (up to 10,000
U/ml) to the suppressed spleen cell cultures was ineffective in reversing the dimin-
ished mitogenic response (data not shown).
Role of TGF-0 in Spleen Cell Suppression.
￿
Macrophages produce additional sup-
pressor molecules including TGFR (21), which we have recently shown to be an ex-
tremely potent inhibitor of IL1-dependent thymocyte proliferation (22). To deter-
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Inhibition of lymphocyte
proliferation by soluble suppressor
factor. Spleen cells(4 x 106/ml) from
control (LC) or three different SCW-
injected (LI1-3) animals were cultured
without stimulation in vitro for 24 h,
andthecell-free supernatants were col-
lected. Thesesupernatants (unconcen-
trated) were diluted as indicated into
control spleen cell cultures challenged
with Con A(5 pg/ml) for72 h. Mito-
genic activity was determined after a
4-h pulse with [3H]TdR.1410
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minewhetherthe solublesuppressor molecule(s)produced bythemacrophages might
be TGFR, the supernatants with suppressor activity were treated with a rabbit an-
tibody to TGF-P (R & DSystems, Inc.) or a control rabbit IgG preparation before
their addition to normal spleen cell cultures. This antibody neutralizes both TGF
/31 and TGF(32. As is evident in Table I, pretreatment of the supernatants from
spleen cell cultures obtained from SCW-treated rats with optimal concentrations
(50 ggIgG/ml) ofthe antiTGFp significantly blocked the suppressor activity ofthese
supernatants causinga 10-fold increasein proliferation. Thecontrol serumwasineffec-
tive in reversing the inhibitory activity. Neutralization of the majority ofthe sup-
pressor activity with an antibody to TGFP suggested coidentity with TGFp, 'al-
though in several experiments suppressor activity could not be completely blocked
even at higher concentrations ofthe antibody. These data suggest that other sup-
pressor molecules in the spleen cell culture supernatants may also contribute to the
immune suppression. Furthermore, addition ofrTGF0 (kindly provided by Genen-
tech) to control spleen cell cultures in nanogram quantities effectively reproduced
the suppressionofnormal spleen cell proliferative responsestoT cellmitogen(Table
II) caused by the suppressor supernatants.
Gene Expression for TGF-Q in Control and SCW Spleens.
￿
To determine whether the
bacterial cell walls induced gene expression forTGF0 in the spleens and/or macro-
phages oftreated animals, spleens were obtained from 12 h to 3 wk after the injec-
tion ofSCW and processed for RNA isolation. When equivalent amounts ofRNA
from control and SCWtreated spleens were hybridized by Northern analysis with
a cDNA probe for TGF0, mRNA levels for TGF-P were not significantly different
in control or SCW-treated spleen cells whether evaluated at 12 h or at 3 wk after
SCW treatment (Fig. 7). Furthermore, the samepatternofTGF-P mRNA expression
was observed when adherent spleen macrophage mRNA was probed for TGFR (data
not shown). These observations are consistent with recent reports that macrophages
constitutively express mRNA for TGF0 and that activation of the cells does not
increase transcription, but rather induces the synthesis and secretion ofTGFp (21).
TABLE I
Antibody to TGF-0 Blocks Suppressor Activity
24-h supernatants (Sup) (100 pl) from SCW-treated rat spleen cell cultures were
incubated with 5 pl PBS, 5 pl rabbit anti-TGF-B antibody, or with an equiva-
lent amount of normal rabbit IgG (NRS) for 30 min before being added (40
pl) to normal spleen cell cultures with or without 5 pg/ml Con A. Normal spleen
cell cultures without any supernatant (none) served as positive controls. After
72 h, the triplicate cultures were pulsed with [3H]TdR and processed for deter-
mination of incorporated [3H]TdR.
Lymphocyte proliferation
Supernatant
([3H]TdR
Control
incorporation)
Con A
cpm
None 1,032 284,593
Sup + PBS 811, 18,506
Sup + NRS 77 13,898
Sup + Anti-TGF-9 319 139,954WAHL ET AL.
￿
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TABLE 11
Suppression of Spleen Cell Proliferation by rTGF-0
Spleen cells (2 x 10 5 ) were stimulated with 0, 1, or 5 pg/ml Con A in the
presence or absence of recombinant TGF-p at the indicated concentrations . Af-
ter 72 h, the cultures were pulsed with [3H]TdR and processed for determina-
tion of incorporated [3H]TdR . Data represent the mean of triplicate cultures .
In Situ Localization of TGF-(3 .
￿
By immunohistochemical localization ofTGF(3,
however, it became clear that although gene expression for TGFR might not be
different in control andSCWinjected spleens, production oftheTGFR gene product
was clearly different in the injected and noninjected spleens . As shown in Fig. 8
C, tissue sections of spleens from SCW-treated animals demonstrated substantial
immunoperoxidase staining with the antibody to TGF(3 in contrast to control spleens
(Fig . 8 F) that were essentially negative forTGFR . Furthermore, the localization
of theTGFp appears to coincide with the phagocytic cells in the spleen . Serial sec-
FIGURE 7 .
￿
Gene expression for
TGFp in spleens from control
and SCW-injected animals .
Spleens were obtained 12 h to
3 wk after an intraperitoneal in-
jection ofSCW (SCYt0 or PBS
(O) and processed for mRNA
isolation . Equivalent amounts
ofRNA on nitrocellulose filters
were hybridized with a 32p-
labeled probe for TGFO . The
filters were exposed to Kodak
XAR5 film with intensifier
screens at -70°C .
TGF-p 0 Vg/ml
Lymphocyte Proliferation
([ 3H]TdR Incorporation [Con A])
1 gg/ml 5 pg/ml
nglml cpm
0 1,720 46,380 24,446
0 .1 1,583 16,560 16,056
1 .0 400 8,883 6,710FIGURE 8.
￿
Immunocytochemical localization ofSCW andTGF-D in spleen sections from con-
trol andSCWinjected animals. Representative serial spleen sections from 3-d SCW-injected (A-C
and control (D-F) animals were stained with hematoxylin and eosin (A andD); with an antibody
to SCW (B andE) ; or with an antibody to TGFP prepared against NH2-terminal residues 1-30
ofTGFP (C and F) by the immunoperoxidase technique . The black precipitate identifies the
reaction product . (x 100) .WAHL ET AL .
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tions of the spleens fromSCWinjected and control animals were stained in parallel
with an antibody toSCW(Fig . 8, BandE) . Areascontaining cells that have phagocy-
tized SCW also contain cells that are positive forTGFR . At higher magnification
(Fig . 9), the colocalization of cells containing SCW and those positive forTGFO
is more apparent . Interestingly, the predominantlyT cell-populated regions stained
minimally or not at all with the antibody for TGF/3 . These in situ data support
the in vitro evidence that the macrophages are the primary source of the suppressor
activity and that this suppressor activity can be attributed, at least in part, to TGFR .
Discussion
TGFR has recently been shown to be a bifunctional regulator of various cellular
and immunologic functions (23). TGF0 can both activate (16) and inhibit (22, 24-28)
immune cell function . While TGFp has been shown to be a potent immunosup-
pressive agent in vitro, no demonstration ofsuch a role haspreviously been documented
in vivo . In this study, we demonstrate that SCW-activated phagocytic cells exert a
profound long-lasting immunosuppressive effect on lymphocyte function in the spleens
of SCW-injected animals . There was no significant change in the percentage of
CD8' and CD4' T lymphocytes in the spleens of the SCW-treated animals . The
only change in the cellular composition of the spleens was an increase in macro-
phage representation . By variouscocultureand depletion techniques, it became ap-
FIGURE 9 .
￿
Immunocytochemical localization ofSCWandTGFp in spleen sections . Spleen sec-
tionsfrom SCW-injected animals stained as above with antibodies to SCW (A) andTGFP (B) .
(x 300).1414
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parent that the adherent cells were involved in the regulation of the SCW-induced
state of immunodeficiency. In culture, the adherent cells (>90% macrophages)
released a soluble molecule into the culture supernatants, which effectively suppressed
normal lymphocyte mitogenesis. Furthermore, this suppressor activity couldbe neu-
tralized with an antibody to TGF-(3 .
Further documentation of a macrophageTGFR pathway for immune suppression
was provided by in situ localization of TGFR in association with the phagocytic cells
ofthe spleens ofSCW-treatedanimals. Interestingly, the mechanism of immunosup-
pression mediated by the SCW-activated phagocytic cells appears to be similar to
previous reports on the mechanism of TGFR-inhibited mitogenesis in vitro (22).
Although TGFR blocked DNA synthesis, it did not block the synthesis of lym-
phokines such as IL-2 northe expression ofIL-2-R on the mitogen-activated T cells
(22) . Lymphocytes obtained from the spleens of SCW-injected animals also did not
proliferate in response to mitogens, yet generated IL-2, GM-CSF, and IL-3 consis-
tent with a TGF-R-mediated block in DNA synthesis, but not cytokine production.
Thepreviously reported deficit in IL-2 production in such cultures (11) maybe related
to a decreased number of IL-2-producing cells rather than a defective synthesis of
IL-2, since reduced IL-2 production is reversible afterremovalofadherent suppressor
cells. IL-1 production also wasnot decreasedand was often increased above the con-
trols as might be anticipated, since TGFR has been shown to induce the synthesis
and secretion of IL-1 (16, 22).
Activated macrophages have frequently been associated with various forms ofim-
munodeficiency, and a number of macrophage-derived suppressor molecules have
been reported includingprostaglandins (19), reactive oxygen intermediates (20), and
a variety of uncharacterized factors produced in response to virus, mycobacteria,
and other stimuli (29-33). The peptidoglycan-polysaccharide polymers ofSCW stimu-
late human (Allen et al., manuscript in preparation) and rat (Feldman et al. manu-
script in preparation) macrophages to generate PGE2, 02 and monokines including
TGFP. The mechanisms of interaction between these andothermacrophage-derived
immunoregulatory molecules in vivo to promote and/or control an inflammatory
response are unclear. However, in the spleens of SCW-injected rats, it appears that
the balance offactorsfavors the ability of TGFa to down-regulate lymphoprolifera-
tive responses.
Many chronic inflammatory conditions, including rheumatoid arthritis (6-10),
leprosy (34), and tuberculosis (35), are associated with deficient cell-mediated im-
mune responses. These abnormalities in immunoregulation have oftenbeen attrib-
uted to an active, adherent, suppressor cell population (10, 36, 37). Although there
is, as yet, no evidence linking TGF0 to the aberrant immune responses in any of
these immunosuppressed conditions, recent evidence from our laboratory suggests
that TGF0 may contribute to the abnormalities in immunoregulation apparent in
the synovium of patients with rheumatoid arthritis (Wahl et al., manuscript sub-
mitted for publication). The unique ability of TGF0 to augment certain aspects
of the immune response while dampening others (16, 22, 23) suggests that it may
play an important immunoregulatory role in chronic inflammatory disorders.
Summary
Group A streptococcal cell wall (SCW)-injected rats exhibit aprofound immunosup-WAHL ET AL.
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pression that persists for months after the initial intraperitoneal injection of SCW.
The goal of this study was to determine the mechanisms for the suppressed T lym-
phocyte proliferative responses in this experimental model of chronic inflammation.
When spleen cell preparations were depleted of adherent cells, restoration of T cell
proliferative responses to Con A and PHA occurred, implicating adherent macro-
phages in the regulation of immunosuppression. Furthermore, macrophages from
SCW-treated animals, when cocultured with normal spleen cells in the presence of
Con A or PHA, effectively inhibited the proliferative response. Supernatants from
suppressed spleen cell cultures were found to inhibit normal T cell mitogenesis. Taken
together, these results implicated a soluble macrophage-derived suppressor factor
in the down regulation of T cell proliferation after exposure to SCW in vivo. Subse-
quent in vitro studies to identify this suppressor molecule(s) revealed the activity
to be indistinguishable from the polypeptide transforming growth factor Q (TGF
(3). Furthermore, TGFR was identified by immunolocalization within the spleens
of SCW-injected animals. The cells within the spleen that stained positively for TGF0
were phagocytic cellsthat had ingested, and were presumably activated by, the SCW.
These studies document that TGF0, previously shown to be a potent immunosup-
pressive agent in vitro, also effectively inhibits immune function in chronic inflam-
matory lesions in vivo.
We gratefullyacknowledge Drs. G. Calandra and R. Wilder for providing streptococcal cell
wall preparations and experimental animals for our preliminary experiments; Drs. H. M.
Shepard and D. Goeddel, Genentech, Inc., for rTGF0 and the TGFO cDNA probe; Ms. S.
Dougherty and Ms. D. Mizel for expert assistance; and Mrs. Paul-Baha for manuscriptprep-
aration.
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